nybanner

        News

        The successor of the blockbuster diet drug Somaglutide

        On July 27, 2023, Lilly announced that the Mount-3 study of Tirzepatide for treating obese patients and the Mount-4 study for maintaining weight loss of obese patients had reached the primary end point and the key secondary end point. This is the third and fourth successful phase III research obtained by Tirzepatide after Mount-1 and Mount-2.

        news31

        SURMOUNT-3 (NCT04657016) is a multicenter, randomized, double-blind, parallel, placebo-controlled trial enrolling a total of 806 participants designed to demonstrate Tirzepatide's superiority over placebo in terms of the percentage change in weight change after randomization and the percentage of participants who lost ≥5% after randomization at 72 weeks.

        The SURMOUNT-3 study results showed that Tirzepatide met all endpoints, namely that after 72 weeks of dosing treatment, patients in the Tirzepatide group achieved a higher percentage of weight loss from baseline compared to placebo, and a higher percentage of patients in the Tirzepatide group achieved a percentage weight loss greater than 5%. Specific clinical data showed that patients treated with Tirzepatide lost an average of 21.1% of body weight compared to placebo; Combined with the 12-week intervention period, patients treated with Tirzepatide lost an average of 26.6 percent of their body weight. In addition, 94.4% of patients lost ≥5% of their weight in the Tirzepatide group, compared with 10.7% in the placebo group.

        SURMOUNT-4 (NCT04660643) is a multicenter, randomized, double-blind, parallel, placebo-controlled trial enrolling a total of 783 participants designed to demonstrate that Tirzepatide was superior to placebo in percentage weight change at 88-week randomization.

        The results showed that after the double-blind period of 37~88 weeks, patients in the Tirzepatide group lost more weight than in the placebo group. In terms of safety, neither the SURMOUNT-3 nor SURMOUNT-4 studies observed new safety signals.

        Since the launch of Novo Nordisk's blockbuster diet drug Semaglutide, coupled with Musk's strong endorsement, it has become a phenomenal Internet celebrity product and the current weight loss king. The weight loss market demand is huge, and there are only two GLP-1 weight loss drugs currently on the market, Liraglutide and Semaglutide, but Liraglutide is a short-acting preparation, which cannot compete with long-acting preparations in terms of patient compliance, and the current weight loss world temporarily belongs to Semaglutide.

        news32

        Also the king of the GLP-1 field, Lilly covets the blue ocean of the weight loss market - so Lilly launched a challenge and first bet on Tirzepatide to seize a place in the weight loss market.

         

        Tirzepatide is a weekly GIPR/GLP-1R dual agonist, GIP (glucose-dependent insulin stimulating polypeptide) is another member of the glucagon peptide family, with the effect of promoting insulin secretion in an insulin-dependent manner and stimulating glucagon secretion in a hypoglycemic state, GIPR/GLP-1R dual agonist can produce blood sugar control, weight loss and other effects by stimulating both GIP and GLP-1 downstream pathways. Tirzepatide has been approved by the FDA in 2022-5 (trade name: Mounjaro) for use in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes.


        Post time: Sep-18-2023
        主站蜘蛛池模板: 亚洲精品亚洲人成人网| 国产成人3p视频免费观看| 久久久久久亚洲精品中文字幕| 波多野结衣和邻居老人| 国产一级黄色片子| 日日夜夜嗷嗷叫| 好男人好资源在线观看免费播放高清| 久久综合久久综合九色| 污污的网站免费观看| 四虎AV永久在线精品免费观看| 欧美亚洲国产激情一区二区| 夜月高清免费在线观看| 中文字幕在线播放一区| 杨幂精品国产福利在线| 亚洲视频中文字幕在线| 老司机午夜福利视频 | 亚洲欧美国产精品| 精品人妻系列无码一区二区三区 | 黑人26厘米大战亚洲女| 国产老妇伦国产熟女老妇视频| 人妻蜜と1~4中文字幕月野定规| 香蕉视频一区二区三区| 国产色视频网免费| 一本大道AV伊人久久综合| 日韩欧美国产三级| 亚洲成av人片在线观看无码| 福利视频1000| 国产一区二区三区免费播放| 欧美一级久久久久久久大片| 国精品午夜福利视频不卡| 一边摸一边叫床一边爽| 日本免费人成视频播放| 亚洲av福利天堂一区二区三| 污小说总裁整夜没拔出| 内射干少妇亚洲69xxx| 要灬要灬再深点受不了好舒服| 国产真人无遮挡作爱免费视频| 97亚洲熟妇自偷自拍另类图片| 婷婷六月综合网| 久久99国产精品久久99果冻传媒 | 国产小视频在线看|